Ownership and insider activity for Bristol-Myers Squibb Company (BMY): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19.
Price
| Price | $58.81 |
| Market Cap | $120.1B |
| Exchange | NYSE |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-30 | YALE PHYLLIS R | A-Award | 560 | |
| 2026-09-30 | Samuels Theodore R. II | A-Award | 821 | |
| 2026-09-30 | Rice Derica W | A-Award | 620 | |
| 2026-09-30 | McMullen Michael R. | A-Award | 560 | |
| 2026-09-30 | Arduini Peter J | A-Award | 560 | |
| 2026-09-09 | Massacesi Cristian | S-Sale | 6,249 | $403K |
| 2026-09-01 | Short Bartie Wendy | M-Exempt | 1,236 | $83K |
| 2026-09-01 | Short Bartie Wendy | F-InKind | 633 | $42K |
| 2026-09-01 | Short Bartie Wendy | M-Exempt | 1,236 | |
| 2026-08-25 | Holzer Phil M | S-Sale | 500 | $34K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.24B | $5.42B | $6.91B | $12.35B | $14.55B | $13.98B | $9.12B | $11.46B | $10.35B | $10.21B |
| Short-term Investments | $2.11B | $1.39B | $1.85B | $3.05B | $1.90B | $3.24B | $130.0M | $816.0M | $513.0M | $464.0M |
| Receivables | $5.54B | $6.30B | $5.75B | $7.68B | $10.55B | $12.52B | $13.94B | $15.26B | $14.42B | $14.53B |
| Inventory | $1.24B | $1.17B | $1.20B | $4.29B | $2.07B | $2.10B | $2.34B | $2.66B | $2.56B | $2.69B |
| Total Current Assets | $13.70B | $14.85B | $17.72B | $29.35B | $30.19B | $33.26B | $27.27B | $31.77B | $29.78B | $29.39B |
| Property, Plant & Equipment | $4.98B | $5.00B | $5.03B | $6.96B | $6.75B | $6.97B | $7.47B | $8.04B | $8.36B | $9.12B |
| Goodwill | $6.88B | $6.86B | $6.54B | $22.49B | $20.55B | $20.50B | $21.15B | $21.17B | $21.72B | $21.75B |
| Intangible Assets | $1.39B | $1.21B | $1.09B | $63.97B | $53.45B | $42.77B | $36.35B | $27.48B | $23.64B | $19.10B |
| Total Assets | $33.71B | $33.55B | $34.99B | $129.94B | $118.48B | $109.31B | $96.82B | $95.16B | $92.60B | $90.04B |
| Accounts Payable | $1.66B | $2.25B | $1.89B | $2.44B | $2.71B | $2.95B | $3.04B | $3.26B | $3.60B | $3.58B |
| Short-term Debt | $992.0M | $987.0M | $1.70B | $3.35B | $2.34B | $4.95B | $4.26B | $3.12B | $2.05B | $2.26B |
| Total Current Liabilities | $8.84B | $9.56B | $10.65B | $18.30B | $19.08B | $21.87B | $21.89B | $22.26B | $23.77B | $23.42B |
| Long-term Debt | $5.72B | $6.97B | $5.65B | $43.39B | $48.34B | $39.60B | $35.06B | $36.65B | $47.60B | $42.85B |
| Total Liabilities | $17.36B | $21.70B | $20.86B | $78.25B | $80.60B | $73.31B | $65.70B | $65.67B | $76.22B | $71.53B |
| Retained Earnings | $33.51B | $31.16B | $34.06B | $34.47B | $21.28B | $23.82B | $25.50B | $28.77B | $14.91B | $16.90B |
| Total Equity | $16.18B | $11.74B | $14.03B | $51.60B | $37.82B | $35.95B | $31.06B | $29.43B | $16.34B | $18.47B |
| Total Debt | $6.71B | $7.96B | $7.35B | $47.54B | $51.67B | $45.60B | $40.72B | $41.46B | $51.20B | $47.14B |
| Net Debt | $358.0M | $1.15B | -$1.41B | $32.15B | $35.22B | $28.38B | $31.46B | $29.18B | $40.34B | $36.47B |
| Working Capital | $4.86B | $5.29B | $7.06B | $11.05B | $11.11B | $11.39B | $5.38B | $9.51B | $6.01B | $5.97B |
Financial Health
| Debt / Equity | 1.93 |
| Current Ratio | 1.53 |
| Piotroski F-Score | 8 |
| Altman Z-Score | 2.30 |
Profitability
| Return on Equity | 46.75% |
| Return on Invested Capital | 15.47% |
| Return on Assets | 10.59% |
| Gross Margin | 70.16% |
| Operating Margin | 28.27% |
| Net Margin | 18.87% |
Related companies: CI · CVS · ELV · GSK · HCA · MCK · PFE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of BMY: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks